You can compare these to mine.
Dementia prevention 19 ways
The calcium antagonist nimodipine did not prevent the decline of cognitive function in patients with acute stroke and mild cognitive impairment, according to a study presented at the International Stroke Conference.
The study included patients between the ages of 30 and 80 years who had a Mini-Mental State Examination (MMSE) score greater than dementia threshold corrected based on educational year, Montreal Cognitive Assessment (MoCA) scores less than 26 for more than 12 educational years and Hachinski scores of 7 or more.
Patients were randomly assigned to receive either 30 mg nimodipine (n = 329) 3 times per day or placebo (n = 325).
The primary endpoint of the study was change in cognitive function as determined by MMSE and Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS–Cog).
Secondary endpoints included changes in score from baseline to 6 months of MoCA and frontal assessment battery.
Zheng said there was no significant difference between the groups in MMSE –3 (OR = 0.56; 95% CI, 0.27-1.26), MMSE 0 (OR = 0.76; 95% CI, 0.55-1.07) or ADAS-Cog 4 (OR = 0.93; 95% CI, 0.52-1.66). For the outcome of ADAS-Cog 0, 34.15% of those assigned nimodipine achieved that threshold vs. 46.74% of those assigned placebo (OR = 0.59; 95% CI, 0.42-0.83).
Key secondary endpoints did not differ between the nimodipine and placebo groups (MoCA: nimodipine group, 1.89; placebo group, 1.66; P = .35; frontal assessment battery: nimodipine group, 0.85; placebo group, 0.67; P = .32).
“Vascular mild cognitive impairment in acute ischemic stroke patients might not benefit from nimodipine in prevention of cognitive function decline when treated 1 week after onset of stroke,” Zheng said during the presentation. “However, nimodipine might have a marginal positive effect on some specific cognitive domains and did not increase risk of stroke and other adverse events.”– by Dave Quaile
Zheng H, et al. LB7. Presented at: International Stroke Conference; Feb. 22-24, 2017; Houston.
Disclosure : The study was funded in part by Bayer HealthCare Pharmaceuticals China. Zheng reports receiving research grants from the National Key Technology Research and Development program of the Ministry of Science and Technology of China.